GlobeNewswire Press

  1. Momotaro-Gene Announces First Patient Dosed In Phase 2 Clinical Trial Of MTG201 In Combination With Nivolumab In Patients With Relapsed Malignant Pleural Mesothelioma 9/11/2019

    Momotaro-Gene, a clinical-stage biotherapeutics company developing novel gene therapies for the treatment of cancer, today announced the dosing of the first patient in a Phase 2 clinical trial combining MTG201, the company’s lead therapeutic candidate, with the PD-1 inhibitor nivolumab (Opdivo®) in patients with relapsed malignant pleural mesothelioma.

  2. CytoDyn Announces FDA Clearance To Proceed With Phase 2 Study Of Leronlimab (PRO 140) And Regorafenib As A Combination Therapy For Metastatic Colorectal Cancer 9/9/2019

    CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has allowed a Phase 2 study to proceed for combination therapy of leronlimab and Regorafenib in patients with metastatic colorectal cancer (mCRC).

  3. Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration With Abbvie 9/4/2019

    Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research-based biopharmaceutical company.

  4. Aduro Biotech Announces First Patient Dosed In Phase 2 Study Of ADU-S100 (MIW815) In Combination With KEYTRUDA® (pembrolizumab) For First-Line Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (HNSCC) 9/4/2019

    Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the first patient has been dosed in a Phase 2 clinical trial of ADU-S100 (MIW815), a novel STING pathway activator, in combination with KEYTRUDA®(pembrolizumab), an approved anti-PD-1 antibody, as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

  5. Taconic Biosciences Participates In Second Rodent Research Reference Mission To The International Space Station 9/3/2019

    Taconic Biosciences, a global leader in providing genetically engineered animal model solutions, announces its participation in the second Rodent Research Reference mission to the International Space Station.

  6. Quantum Genomics Announces Positive FDA Feedback On Phase III Program Design Of Firibastat In Resistant Arterial Hypertension 9/2/2019

    Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant arterial hypertension and heart failure, today announced that it met a new milestone of its strategic plan by receiving favourable feedback from the U.S. Food and Drug Administration (FDA) regarding the Company’s Phase III development plan and trial design for firibastat in patients with resistant arterial hypertension.

  7. Outlook Therapeutics Completes Patient Enrollment For NORSE 1 A Phase 3 Clinical Trial For ONS-5010 In Wet AMD 8/20/2019

    Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that it has completed patient enrollment in the NORSE 1 Phase 3 clinical trial, which is evaluating ONS-5010 against ranibizumab (Lucentis®) for wet AMD.

  8. Emendo Biotherapeutics Achieves Milestone Of Collaboration With Takeda For Its OMNI Nuclease Program 8/20/2019

    Emendo Biotherapeutics today announced that the company achieved the first milestone as laid out in the agreements with Takeda Pharmaceutical Company Limited (Takeda), resulting in the transfer of the second half of the investment from Takeda to Emendo and completion of funding of the convertible notes agreement signed on Feb 1, 2019.

  9. ReNetX Bio Announces Initiation Of Patient Dosing In The First Phase 1 Clinical Trial Of Fusion Protein AXER-204 8/14/2019

    ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system (CNS) disorders, has announced a successful first patient dosing in a Phase 1 clinical trial of its lead drug candidate, fusion protein AXER-204.

  10. Hepion Pharmaceuticals Announces Dosing Of First HBV Patient In 28-Day Study Of CRV431 8/14/2019

    Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that it has dosed the first patient in a 28-day multiple ascending dose clinical trial of CRV431.